Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 10 | 2024 | 1691 | 0.550 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2018 | 477 | 0.540 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2024 | 821 | 0.530 |
Why?
|
| Radiosurgery | 2 | 2023 | 106 | 0.390 |
Why?
|
| Neuroblastoma | 6 | 2017 | 513 | 0.360 |
Why?
|
| Antigens, CD19 | 5 | 2024 | 177 | 0.350 |
Why?
|
| Gangliosides | 2 | 2024 | 63 | 0.310 |
Why?
|
| Interleukin-2 | 5 | 2017 | 224 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 162 | 0.280 |
Why?
|
| Bone Marrow Cells | 3 | 2016 | 260 | 0.230 |
Why?
|
| Cell Culture Techniques | 3 | 2014 | 287 | 0.220 |
Why?
|
| Killer Cells, Natural | 3 | 2017 | 320 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 64 | 0.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2016 | 182 | 0.210 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 430 | 0.210 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 83 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 194 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2022 | 206 | 0.190 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2016 | 80 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 332 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 229 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 489 | 0.160 |
Why?
|
| Cancer Vaccines | 3 | 2007 | 186 | 0.160 |
Why?
|
| Oxygen | 1 | 2022 | 547 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 764 | 0.140 |
Why?
|
| Ki-1 Antigen | 1 | 2017 | 27 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 46 | 0.140 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 35 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 113 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 100 | 0.130 |
Why?
|
| CD28 Antigens | 2 | 2017 | 78 | 0.130 |
Why?
|
| Sialoglycoproteins | 2 | 2007 | 48 | 0.120 |
Why?
|
| Genetic Therapy | 3 | 2022 | 678 | 0.120 |
Why?
|
| Lymphokines | 2 | 2007 | 66 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 293 | 0.120 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 237 | 0.120 |
Why?
|
| Immunophenotyping | 5 | 2017 | 328 | 0.120 |
Why?
|
| Immunotherapy | 3 | 2015 | 662 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 1591 | 0.110 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 157 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 194 | 0.100 |
Why?
|
| K562 Cells | 1 | 2012 | 95 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 324 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 533 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 502 | 0.090 |
Why?
|
| Cytokines | 5 | 2017 | 1284 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 518 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 1200 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 663 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2018 | 12123 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 137 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2011 | 501 | 0.080 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.080 |
Why?
|
| Humans | 23 | 2024 | 123070 | 0.080 |
Why?
|
| Lymphocyte Activation | 4 | 2012 | 684 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 472 | 0.070 |
Why?
|
| Lymphoma | 1 | 2011 | 324 | 0.070 |
Why?
|
| Male | 15 | 2024 | 60080 | 0.070 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2007 | 12 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 130 | 0.070 |
Why?
|
| Young Adult | 5 | 2024 | 8837 | 0.070 |
Why?
|
| Female | 15 | 2024 | 65529 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 805 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1232 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 393 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2005 | 64 | 0.060 |
Why?
|
| Child | 10 | 2024 | 24226 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2022 | 1909 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 323 | 0.060 |
Why?
|
| Child, Preschool | 7 | 2024 | 13881 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1118 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 353 | 0.060 |
Why?
|
| Adolescent | 8 | 2024 | 19096 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1238 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 238 | 0.060 |
Why?
|
| Retroviridae | 2 | 2016 | 194 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 268 | 0.050 |
Why?
|
| Chemokines, C | 1 | 2002 | 10 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 90 | 0.050 |
Why?
|
| Thymidine | 1 | 2022 | 54 | 0.050 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 297 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2022 | 95 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2022 | 3042 | 0.050 |
Why?
|
| Cell Survival | 2 | 2016 | 809 | 0.050 |
Why?
|
| Cryopreservation | 2 | 2013 | 82 | 0.050 |
Why?
|
| Leukemia | 1 | 2005 | 375 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 263 | 0.050 |
Why?
|
| Middle Aged | 6 | 2018 | 25993 | 0.050 |
Why?
|
| Myeloid Cells | 2 | 2017 | 98 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 289 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2003 | 217 | 0.050 |
Why?
|
| Sirolimus | 1 | 2022 | 220 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 1419 | 0.040 |
Why?
|
| Remission Induction | 2 | 2016 | 299 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 157 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2022 | 2307 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 426 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 286 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1161 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 2055 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 496 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 659 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 78 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2017 | 45 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 36 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 115 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 1008 | 0.030 |
Why?
|
| Suspensions | 1 | 2016 | 9 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 124 | 0.030 |
Why?
|
| Iohexol | 1 | 2016 | 20 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1661 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2008 | 126 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Aged | 3 | 2018 | 19095 | 0.030 |
Why?
|
| Adult | 4 | 2017 | 29011 | 0.030 |
Why?
|
| Heparin | 1 | 2016 | 227 | 0.030 |
Why?
|
| Transduction, Genetic | 2 | 2008 | 290 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 393 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 376 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 413 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 810 | 0.030 |
Why?
|
| Infant | 3 | 2024 | 12355 | 0.030 |
Why?
|
| Bioreactors | 1 | 2014 | 38 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 116 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1683 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 752 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 57 | 0.030 |
Why?
|
| 4-1BB Ligand | 1 | 2012 | 11 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 653 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 2012 | 32 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 3293 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 340 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1004 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 257 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 269 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 96 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 12 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2012 | 91 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 24 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2023 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2011 | 121 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 608 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 184 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 803 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 752 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1565 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 4703 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3654 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6372 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6222 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 161 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 77 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 1473 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3544 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 2003 | 34 | 0.010 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 16 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2771 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2002 | 33 | 0.010 |
Why?
|
| Panniculitis | 1 | 2002 | 19 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 101 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5048 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 230 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2002 | 187 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 462 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 947 | 0.010 |
Why?
|
| Epitopes | 1 | 2003 | 429 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2003 | 402 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2002 | 193 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1061 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 769 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 506 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 4221 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 33791 | 0.010 |
Why?
|